{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-026567","form_type":"8-K","ticker":"RVPH","cik":"0001742927","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2024-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.382480+00:00","generated_at":"2026-05-31T09:22:38.374276+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Reviva Q2 2024 net loss $7.9M; cash $6.2M; OLE topline data expected Q4 2024","bullets":["Net loss of $7.9M ($0.26/sh) vs $11.7M ($0.52/sh) in Q2 2023; six-month loss $15.3M ($0.51/sh).","Cash $6.2M at June 30, 2024, down from $23.4M at Dec 31, 2023.","Topline data from 1-year OLE trial in schizophrenia expected Q4 2024; registrational RECOVER-2 trial to start Q3 2024.","U.S. patent granted for brilaroxazine in IPF; European patent for pulmonary hypertension; both received Orphan Drug Designation."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-026567","json":"https://secwatch.observer/filing/0001437749-24-026567.json","markdown":"https://secwatch.observer/filing/0001437749-24-026567.md","text":"https://secwatch.observer/filing/0001437749-24-026567.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1742927/000143774924026567/0001437749-24-026567-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1742927/000143774924026567/rvph20240807_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:22:38.374276+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}